{"filing":{"accession_number":"0002019410-26-000053","cik":"0002019410","ticker":"CAI","company_name":"Caris Life Sciences, Inc.","form":"8-K","filing_date":"2026-08-05","report_date":"2026-08-05","primary_document":"cai-20260805.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2019410/000201941026000053/cai-20260805.htm"},"events":[{"id":25303,"run_id":22960,"accession_number":"0002019410-26-000053","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"Caris Life Sciences issued a press release on August 5, 2026 announcing Q2 2026 financial results, including total revenue of $263.7 million (45% growth), gross margin of 68%, net loss of $0.6 million, and positive Adjusted EBITDA of $55.7 million. The company also raised its 2026 full-year revenue guidance to $1.03–$1.04 billion (27–28% growth). This is a standard quarterly earnings release with detailed financial statements and forward guidance, filed under Item 2.02 and furnished as Exhibit 99.1.","company_name":"Caris Life Sciences, Inc.","ticker":"CAI","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":26091,"accession_number":"0002019410-26-000053","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Caris Life Sciences issued a press release on August 5, 2026 announcing Q2 2026 financial results, including total revenue of $263.7 million (45% growth), gross margin of 68%, net loss of $0.6 million, and positive Adjusted EBITDA of $55.7 million. The company also raised its 2026 full-year revenue guidance to $1.03–$1.04 billion (27–28% growth). This is a standard quarterly earnings release with detailed financial statements and forward guidance, filed under Item 2.02 and furnished as Exhibit 99.1.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:30:23.517810+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26091,"accession_number":"0002019410-26-000053","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Caris Life Sciences issued a press release on August 5, 2026 announcing Q2 2026 financial results, including total revenue of $263.7 million (45% growth), gross margin of 68%, net loss of $0.6 million, and positive Adjusted EBITDA of $55.7 million. The company also raised its 2026 full-year revenue guidance to $1.03–$1.04 billion (27–28% growth). This is a standard quarterly earnings release with detailed financial statements and forward guidance, filed under Item 2.02 and furnished as Exhibit 99.1.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:30:23.517810+00:00","company_name":"Caris Life Sciences, Inc.","ticker":"CAI","filing_date":"2026-08-05"}]}